Cader, Fathima ZumlaHu, XihaoGoh, Walter L.Wienand, KirstyOuyang, JingMandato, ElisaRedd, RobertLawton, LeeChen, Pei-HsuanWeirather, Jason L.Schackmann, Ron C. J.Li, BoMa, WenjiangArmand, PhilippeRodig, ScottNeuberg, DonnaLiu, X. ShirleyShipp, Margaret A.shipp2022-05-272020-08-10Cader, Fathima Zumla, Hu, Xihao, Goh, Walter L, Wienand, Kirsty, Ouyang, Jing, Mandato, Elisa, and Redd, Robert. "A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in Patients with Classical Hodgkin Lymphoma." Nature Medicine 26, no. 9 (2020): 1468-479.1078-89561546-170Xhttps://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37371790PD-1 blockade is highly effective in classical Hodgkin lymphoma although the mechanism of action in this largely MHC class I-negative tumor remains undefined. Given this conundrum, we utilized the complementary approaches of T-cell receptor (TCR) sequencing and cytometry by time-of-flight analysis to obtain a peripheral immune signature of responsiveness to PD-1 blockade in clinical trial patients. Increased total and CD4+ TCR repertoire diversity and clonal expansion of singleton T cells were associated with response to anti PD-1 therapy. Additionally, responding patients had an increased abundance of activated NK cells and a newly identified CD3-CD68+CD4+GrB+ subset suggesting a complementary role for innate immunity in the efficacy of PD-1 blockade.en-USGeneral Biochemistry, Genetics and Molecular BiologyGeneral MedicineJournal Article2022-05-2710.1038/s41591-020-1006-1